

## ASX ANNOUNCEMENT MARKET RELEASE

20 June 2022

### ARTRYA APPOINTS ACCOMPLISHED AMERICAN PHYSICIAN AS CMO

#### Key Points:

- New York based Dr Jacob Agris appointed as new Chief Medical Officer for Artrya Limited.
- Dr Agris is a Senior Health Care Executive, Thought Leader and accomplished physician with unique computer engineering doctoral studies in analytics and Machine Learning.
- Dr Agris will lead Artrya's medical affairs strategy, clinical development and FDA interaction.

Perth, Western Australia., (20 Jun 2022) – Australian medical technology company, Artrya Limited (ASX: AYA, Artrya or the Company) is announcing the appointment of accomplished US physician, senior health care executive and thought leader, Dr Jacob Agris, MD, PhD, as its new Chief Medical Officer effective today. Dr Agris will oversee all medical affairs strategy, clinical development, FDA and global regulatory interactions as well as being a strategic partner and advisor to the CEO and leadership team.

Artrya Managing Director and CEO, John Barrington AM, said he is delighted to welcome Dr Jacob Agris to the Company.

“Dr Agris brings a remarkable breadth of knowledge as a practising physician and recognised leader in data analytics and AI with particular experience leading development of AI for Health Care and navigating regulatory approvals for clinical use.”

“There is no doubt he will be a great asset to the Company with experience spanning C-suite roles, Fortune 500 companies and as an accomplished physician with a unique blend of computer engineering doctoral studies in data analytics and Machine Learning. Together with his track record as an innovator and founding entrepreneur of dynamic start-ups, Dr Agris is perfectly positioned to lead Artrya's medical affairs as we grow and evolve as a company,” Mr Barrington said.

With the expansion of Artrya in the US, the appointment of Dr Agris to a full-time role in New York is timely.

As research is key to driving Artrya's innovation, former CMO Professor Girish Dwivedi will now take on the role of Chief Scientific Officer, leveraging his world-renowned research expertise in coronary plaque.

#### About Artrya

Based in Perth, Western Australia, Artrya was founded in 2018 and commenced operations in early 2019. Artrya Ltd is listed on the Australian Securities Exchange (ASX: AYA). Artrya is an applied artificial intelligence healthcare company that works alongside clinicians to improve the diagnosis of coronary

artery disease and develop a holistic overview of a patient at risk. Artrya has developed deep learning algorithms that will streamline how medical care for heart disease is delivered.

Artrya USA Inc. is a wholly owned subsidiary of Artrya Limited.

For more information: [www.artrya.com](http://www.artrya.com)

This announcement was approved by the Company's Managing Director and CEO, John Barrington, on behalf of the Artrya Board.

For further information please contact:

Investor Enquiries:  
John Barrington  
Artrya Limited  
+61 419 850 502  
investors@artrya.com

Media Enquiries:  
Felicity Heath  
Daymark  
+61 457 196 603  
felicity.heath@daymark.com.au

---

#### About Dr J. Agris

Jacob Agris, MD, PhD is a proven leader at the intersection of R&D, technology and healthcare. It is rare to find someone of this calibre with the breadth of expertise and depth of experience, which makes him a tremendous fit. He is an academic physician, a leading scientist, a technology expert and an influential leader.

Jacob Agris, MD, PhD was previously the Chief Medical and Innovation Officer at Convatec where he was responsible for the corporate medical function, clinical compliance and AI and data analytics strategy. He implemented a clinical data warehouse in the cloud enabling rapid development of AI-based Software as a Medical Device (SaMD) applications for both wound care and urology that fused imaging, EHR and wearable technology and are now in clinical trials. He has held leadership roles as Head of Medical Affairs and the Medical Digital Advisor to R&D at Bayer where he established a vision and roadmap for the company's radiology digital business and led the clinical development and medical support for submissions of Software as a Medical Device for radiology and cardiology applications as well as pharma products, ensuring digital solutions are improving care for patients.

He has an excellent track record with the FDA in this space where he has been involved in more than 20 Class 1, Class 2 (both 510k and de novo) and NDA submissions and helped obtain approval for two submissions that were not initially approved. He has a deep understanding of Cloud AI and what data is needed for 510k and de novo submissions for SaMD. Among his achievements, he was instrumental in the development and breakthrough device designation by the FDA for CTEPH.AI, deep learning software applied to Chest CT. He led development for this joint software project between Bayer and Merck to analyse cardiac, vascular and pulmonary findings to diagnose a rare form of treatable pulmonary hypertension (CTEPH), a life-threatening complication of pulmonary embolus. Previous to this he was also involved in the clinical development for Bayer's Radimetrics digital platform, which is cleared by the FDA and is a market leader

supporting 26 million patient studies for radiology and cardiology. He will work closely with the FDA to insure that Artrya software is cleared for use in the US and globally.

Prior to joining industry, Jacob was an academic physician highly respected for his clinical care and leadership in clinical roles. He was an Interventional Neuroradiologist and Co-director of the Stroke Program at Saint Vincent Hospital System (Allegheny Health Network) and he was Assistant Professor and Section Chief for Interventional Neuroradiology at Virginia Commonwealth University Medical Center.

Jacob holds both a Doctorate of Medicine from Baylor College of Medicine (BCM), Texas and a Ph.D. in Electrical & Computer Engineering, which he completed at Rice University, Texas funded by National Institutes of Health (NIH). He undertook postdoctoral medical training at several institutions (including Boston Medical Center, University of Maryland Medical Center and John Hopkins Hospital in Baltimore, Maryland as well as being a Keck Fellow at the BCM Center for Structural Biology). He also holds a Bachelor of Science degree In Biomedical Engineering from Rensselaer Polytechnic Institute in New York State. He has over 100 abstracts/publications and patents related to healthcare.